ScholarIQanswers from OpenAlex & ORCID
Baljit Singh
ResearcherPublications, citations & collaboration network
Baljit Singh is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Baljit Singh have?
ScholarIQindexed works
Baljit Singh has 498 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Baljit Singh have?
ScholarIQcitation count
Baljit Singh has 16,989 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Baljit Singh?
ScholarIQh-index
Baljit Singh has an h-index of 59 in OpenAlex.
What is the i10-index of Baljit Singh?
ScholarIQi10-index
Baljit Singh has an i10-index of 217 in OpenAlex.
What is the ORCID of Baljit Singh?
ScholarIQorcid
The ORCID for Baljit Singh is on the source record.
What is the OpenAlex record for Baljit Singh?
ScholarIQopenalex
The OpenAlex for Baljit Singh is on the source record.
What are the most-cited papers on Baljit Singh?
ScholarIQmost cited works
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A. Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen Van de Vijver, Mónica V. Estrada, Paula I. González-Ericsson, Melinda Sanders, Benjamin Solomon, Cinzia Solinas, Gert G. G. M. Van den Eynden, Yves Allory, Matthias Preusser, Johannes A. Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nucíforo, Laura Comerma, E. Aubrey Thompson, Sunil R. Lakhani, Seong-Rim Kim, Stuart J. Schnitt, Cécile Colpaert, Christos Sotiriou, Stefan Scherer, Michail Ignatiadis, Sunil Badve, Robert H. Pierce, Giuseppe Viale, Nicolas Sirtaine, Frédérique Penault‐Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea L. Richardson, Yihong Wang, Ewa Chmielik, Jane Brock, Douglas B. Johnson, Justin M. Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternès, Nicole Burchardi, Stephen J. Luen, Peter Savas, Frederick Klauschen, Peter H. Watson, Brad H. Nelson, Carmen Criscitiello, Sandra A. O’Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix‐Triki, Marc J. van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph A. Sparano, David L. Rimm, Torsten O. Nielsen, Zuzana Kos, Stephen M. Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H. Allison, Nadine Tung, Sylvia Adams, Karen Willard‐Gallo, Hugo M. Horlings, Leena Gandhi, André Moreira, Fred R. Hirsch, Maria Vittoria Dieci, María Urbanowicz, Iva Brčić, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer M. Giltnane, Marlon C. Rebelatto, Keith E. Steele, Jiping Zha, Kenneth Emancipator, Jonathan Juco, Carsten Denkert, Jorge S. Reis‐Filho, Sherene Loi, Stephen B. Fox
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research
Shona Hendry, Roberto Salgado, Thomas Gevaert, Prudence A. Russell, Tom John, Bibhusal Thapa, Michael Christie, Koen Van de Vijver, Mónica V. Estrada, Paula I. González-Ericsson, Melinda E. Sanders, Benjamin Solomon, Cinzia Solinas, Gert G. G. M. Van den Eynden, Yves Allory, Matthias Preusser, Johannes A. Hainfellner, Giancarlo Pruneri, Andrea Vingiani, Sandra Demaria, Fraser Symmans, Paolo Nucíforo, Laura Comerma, E. Aubrey Thompson, Sunil R. Lakhani, Seong-Rim Kim, Stuart J. Schnitt, Cécile Colpaert, Christos Sotiriou, Stefan Scherer, Michail Ignatiadis, Sunil Badve, Robert H. Pierce, Giuseppe Viale, Nicolas Sirtaine, Frédérique Penault‐Llorca, Tomohagu Sugie, Susan Fineberg, Soonmyung Paik, Ashok Srinivasan, Andrea L. Richardson, Yihong Wang, Ewa Chmielik, Jane B. Brock, Douglas B. Johnson, Justin M. Balko, Stephan Wienert, Veerle Bossuyt, Stefan Michiels, Nils Ternès, Nicole Burchardi, Stephen J. Luen, Peter Savas, Frederick Klauschen, Peter H. Watson, Brad H. Nelson, Carmen Criscitiello, Sandra A. O’Toole, Denis Larsimont, Roland de Wind, Giuseppe Curigliano, Fabrice André, Magali Lacroix‐Triki, Marc J. van de Vijver, Federico Rojo, Giuseppe Floris, Shahinaz Bedri, Joseph A. Sparano, David L. Rimm, Torsten O. Nielsen, Zuzana Kos, Stephen M. Hewitt, Baljit Singh, Gelareh Farshid, Sibylle Loibl, Kimberly H. Allison, Nadine Tung, Sylvia Adams, Karen Willard‐Gallo, Hugo M. Horlings, Leena Gandhi, André L. Moreira, Fred R. Hirsch, Maria Vittoria Dieci, María Urbanowicz, Iva Brčić, Konstanty Korski, Fabien Gaire, Hartmut Koeppen, Amy Lo, Jennifer M. Giltnane, Marlon C. Rebelatto, Keith E. Steele, Jiping Zha, Kenneth Emancipator, Jonathan Juco, Carsten Denkert, Jorge S. Reis‐Filho, Sherene Loi, Stephen B. Fox
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib
Lisa A. Carey, Donald A. Berry, Constance Cirrincione, William T. Barry, Brandelyn N. Pitcher, Lyndsay N. Harris, David W. Ollila, Ian E. Krop, N. Lynn Henry, Douglas Weckstein, Carey K. Anders, Baljit Singh, Katherine A. Hoadley, Michael D. Iglesia, Maggie C.U. Cheang, Charles M. Perou, Eric P. Winer, Clifford A. Hudis